Aida Falgas

Madrid, MD, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications

CD22 CAR-T cells secreting CD19 T-cell engagers for improved control of B-cell acute lymphoblastic leukemia progression.

CD22 CAR-T cells secreting CD19 T-cell engagers for improved control of B-cell acute lymphoblastic leukemia progression.

Journal: Journal for immunotherapy of cancer
Published: April 07, 2025

CAR-T cells targeting CCR9 and CD1a for the treatment of T cell acute lymphoblastic leukemia.

CAR-T cells targeting CCR9 and CD1a for the treatment of T cell acute lymphoblastic leukemia.

Journal: Journal of hematology & oncology
Published: November 05, 2024

NSGS mice humanized with cord blood mononuclear cells show sustained and functional myeloid-lymphoid representation with limited graft-versus-host disease.

NSGS mice humanized with cord blood mononuclear cells show sustained and functional myeloid-lymphoid representation with limited graft-versus-host disease.

Journal: Journal for immunotherapy of cancer
Published: September 16, 2024

A TIM-3-Fc decoy secreted by engineered T cells improves CD19 CAR T-cell therapy in B-cell acute lymphoblastic leukemia.

A TIM-3-Fc decoy secreted by engineered T cells improves CD19 CAR T-cell therapy in B-cell acute lymphoblastic leukemia.

Journal: Blood
Published: May 16, 2024

Engineered T cells secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivo.

Engineered T cells secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivo.

Journal: Science translational medicine
Published: February 14, 2024

NG2 is a target gene of MLL-AF4 and underlies glucocorticoid resistance in MLLr B-ALL by regulating NR3C1 expression.

NG2 is a target gene of MLL-AF4 and underlies glucocorticoid resistance in MLLr B-ALL by regulating NR3C1 expression.

Journal: Blood
Published: August 14, 2023

T22-PE24-H6 Nanotoxin Selectively Kills CXCR4-High Expressing AML Patient Cells In Vitro and Potently Blocks Dissemination In Vivo.

T22-PE24-H6 Nanotoxin Selectively Kills CXCR4-High Expressing AML Patient Cells In Vitro and Potently Blocks Dissemination In Vivo.

Journal: Pharmaceutics
Published: January 31, 2023

A diphtheria toxin-based nanoparticle achieves specific cytotoxic effect on CXCR4+ lymphoma cells without toxicity in immunocompromised and immunocompetent mice.

A diphtheria toxin-based nanoparticle achieves specific cytotoxic effect on CXCR4+ lymphoma cells without toxicity in immunocompromised and immunocompetent mice.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: February 21, 2022

Time-Prolonged Release of Tumor-Targeted Protein-MMAE Nanoconjugates from Implantable Hybrid Materials.

Time-Prolonged Release of Tumor-Targeted Protein-MMAE Nanoconjugates from Implantable Hybrid Materials.

Journal: Pharmaceutics
Published: December 15, 2021

Engineering non-antibody human proteins as efficient scaffolds for selective, receptor-targeted drug delivery.

Engineering non-antibody human proteins as efficient scaffolds for selective, receptor-targeted drug delivery.

Journal: Journal of controlled release : official journal of the Controlled Release Society
Published: October 01, 2021

A multivalent Ara-C-prodrug nanoconjugate achieves selective ablation of leukemic cells in an acute myeloid leukemia mouse model.

A multivalent Ara-C-prodrug nanoconjugate achieves selective ablation of leukemic cells in an acute myeloid leukemia mouse model.

Journal: Biomaterials
Published: May 26, 2021

Biparatopic Protein Nanoparticles for the Precision Therapy of CXCR4+ Cancers.

Biparatopic Protein Nanoparticles for the Precision Therapy of CXCR4+ Cancers.

Journal: Cancers
Published: April 10, 2021
Showing 1-12 of 22

Last Updated: 09/26/2026